Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan
GG Sokos, A Raina - Vascular Health and Risk Management, 2020 - Taylor & Francis
This review aims to elucidate the optimal dosing of angiotensin receptor-neprilysin inhibitor
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …
Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan
GG Sokos, A Raina - Vascular health and risk …, 2020 - pubmed.ncbi.nlm.nih.gov
This review aims to elucidate the optimal dosing of angiotensin receptor-neprilysin inhibitor
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …
Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.
GG Sokos, A Raina - Vascular Health and Risk Management, 2020 - europepmc.org
This review aims to elucidate the optimal dosing of angiotensin receptor-neprilysin inhibitor
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …
Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan
GG Sokos, A Raina - Vascular Health and Risk Management, 2020 - search.proquest.com
This review aims to elucidate the optimal dosing of angiotensin receptor-neprilysin inhibitor
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …
[HTML][HTML] Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan
GG Sokos, A Raina - Vascular Health and Risk Management, 2020 - ncbi.nlm.nih.gov
This review aims to elucidate the optimal dosing of angiotensin receptor-neprilysin inhibitor
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …
Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan
GG Sokos, A Raina - Vascular Health and Risk Management, 2020 - dovepress.com
This review aims to elucidate the optimal dosing of angiotensin receptor-neprilysin inhibitor
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …
Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.
GG Sokos, A Raina - Vascular Health and Risk Management, 2020 - go.gale.com
This review aims to elucidate the optimal dosing of angiotensin receptor-neprilysin inhibitor
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …